[WBB Securities invites you to attend the upcoming Demy-Colton Virtual Salon titled: “Seven Years After FDA Approval: What Have We Learned About Cell and Gene Therapies?”.](https://wbbsec.com/press-releases/wbb-securities-invites-you-to-attend-the-upcoming-demy-colton-virtual-salon-titled-seven-years-after-fda-approval-what-have-we-learned-about-cell-and-gene-therapies/)
[WBB Securities invites you to attend the upcoming Demy-Colton Virtual Salon titled: “Seven Years After FDA Approval: What Have We Learned About Cell and Gene Therapies?”.](https://wbbsec.com/press-releases/wbb-securities-invites-you-to-attend-the-upcoming-demy-colton-virtual-salon-titled-seven-years-after-fda-approval-what-have-we-learned-about-cell-and-gene-therapies/)

Analyst Interview with Steve Brozak: Big-Picture Biotech Stocks Rule the Future

By:Posted: Sep 8th, 2014In: Opinions & Features

9.8.14 | The Life Sciences Report

When Steve Brozak performs diligence on biotech stocks, he’s always looking for an angle. Brozak, president and managing director at WBB Securities, wants to see how new technology platforms and novel ideas fit into tomorrow’s healthcare system, which he believes will be unsustainable without therapies that work more efficiently and hold promise as true disease-modifying agents. In this interview with The Life Sciences Report, Brozak brings eight names to investors’ attention.  For the full article, please click here.

Recent Posts